Cargando…
A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer
INTRODUCTION: For patients with advanced epithelial ovarian cancer, complete surgical cytoreduction remains the strongest predictor of outcome. However, identifying patients who are likely to benefit from such surgery remains elusive and to date few surgical outcome prediction tools have been valida...
Autores principales: | Hawarden, Amy, Price, Marcus, Russell, Bryn, Wilson, Godfrey, Farrelly, Laura, Embleton-Thirsk, Andrew, Parmar, Mahesh, Edmondson, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035831/ https://www.ncbi.nlm.nih.gov/pubmed/36952534 http://dx.doi.org/10.1371/journal.pone.0281798 |
Ejemplares similares
-
Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study
por: Hawarden, Amy, et al.
Publicado: (2021) -
Correction to: Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study
por: Hawarden, Amy, et al.
Publicado: (2021) -
The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome
por: Walker, Thomas D. J., et al.
Publicado: (2023) -
Impact of retrospective data verification to prepare the ICON6 trial
for use in a marketing authorization application
por: Embleton-Thirsk, Andrew, et al.
Publicado: (2019) -
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
por: Ledermann, J.A., et al.
Publicado: (2021)